PROGRAM AGENDA
| 08:00 – 08:30 08:00 | 08:30 | Registration | |
| 08:30 – 08:35 08:30 | 08:35 |
Opening Remarks
|
|
| 08:35 – 10:40 08:35 | 10:40 | MYELOPROLIFERATIVE NEOPLASMS | |
| Moderators: , , | ||
| 08:35 – 09:00 08:35 | 09:00 |
MPN Updates and the Evolution of the Diseases
|
|
| 09:00 – 09:20 09:00 | 09:20 |
The Myeloproliferative Neoplasms: Acquired Genetics and A Big Surprise
|
|
| 09:20 – 09:40 09:20 | 09:40 |
Genetic Heterogeneity & Rare Variants in MPN
|
|
| 09:40 – 10:00 09:40 | 10:00 |
Targeting the MPN Stem Cell and Molecular Response as a Surrogate for Survival
|
|
| 10:00 – 10:20 10:00 | 10:20 | Panel Discussion | |
| 10:20 – 10:40 10:20 | 10:40 | BREAK | |
| 10:40 – 13:00 10:40 | 13:00 | MYELOFIBROSIS | |
| Moderators: , , | ||
| 10:40 – 11:00 10:40 | 11:00 |
Modern Management of Myelofibrosis
|
|
| 11:00 – 11:20 11:00 | 11:20 |
Clinical and Molecular Genetic Characterization of Myelofibrosis
|
|
| 11:20 – 11:40 11:20 | 11:40 |
Early Intervention in Myelofibrosis
|
|
| 11:40 – 00:00 11:40 | 00:00 | Panel Discussion | |
| 12:00 – 13:00 12:00 | 13:00 | LUNCH | |
| 13:00 – 15:00 13:00 | 15:00 | POLYCYTHEMIA VERA | |
| Moderators: , , | ||
| 13:00 – 13:20 13:00 | 13:20 |
What's New in Polycythemia Vera
|
|
| 13:20 – 13:40 13:20 | 13:40 |
Early Intervention in Polycythemia Vera
|
|
| 13:40 – 14:00 13:40 | 14:00 |
Ropeg-IFN-α Selectively Suppresses JAK2 V617F Clones in PV Treatment
|
|
| 14:00 – 14:20 14:00 | 14:20 |
Predictors of Treatment Response in PV Treated with Ropeginterferon alfa-2b
|
|
| 14:20 – 14:40 14:20 | 14:40 | Panel Discussion | |
| 14:40 – 15:00 14:40 | 15:00 | BREAK | |
| 15:00 – 18:05 15:00 | 18:05 | ESSENTIAL THROMBOCYTOSIS AND CLINICAL EXPERIENCE SHARING | |
| Moderators: , , , , | ||
| 15:00 – 15:20 15:00 | 15:20 |
Therapeutic Advances & Clinical Trials in ET
|
|
| 15:20 – 15:40 15:20 | 15:40 |
Real-World Experience: Prospective Ropeginterferon Alfa- 2b Therapy in PV & ET
|
|
| 15:40 – 16:00 15:40 | 16:00 |
From Dosing Strategy to Clinical Benefit: Rethinking Interferon Use Patterns to Optimize Efficacy and Safety
|
|
| 16:00 – 16:20 16:00 | 16:20 |
From Gene to Clinic: Translating Molecular Discoveries into Management Strategies in MPNs
|
|
| 16:20 – 16:40 16:20 | 16:40 | BREAK | |
| 16:40 – 17:00 16:40 | 17:00 |
Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)
|
|
| 17:00 – 17:20 17:00 | 17:20 |
Metformin Alleviates Side Effects and Supports the Resumption of Interferon Therapy in PV and ET
|
|
| 17:20 – 17:40 17:20 | 17:40 |
Myeloproliferative Neoplasm Subtype Impacts Risk of Incident Osteoporosis and Osteoporotic Fractures
|
|
| 17:40 – 18:00 17:40 | 18:00 | Panel Discussion | |
| 18:00 – 18:05 18:00 | 18:05 |
Closing Remarks
|
|